Esophageal cancer

Jaffer A. Ajani, James S. Barthel, Tanios Bekaii-Saab, David J. Bentrem, Thomas A. D'Amico, Charles S. Fuchs, Hans Gerdes, James A. Hayman, Lisa Hazard, David H. Ilsonn, Lawrence R. Kleinberg, Mary Frances McAleer, Neal J. Meropol, Mary F. Mulcahy, Mark B. Orringer, Raymund U. Osarogiagbon, James A. Posey, Aaron R. Sasson, Walter J. Scott, Stephen ShibataVivian E.M. Strong, Stephen G. Swisher, Mary Kay Washington, Christopher Willett, Douglas E. Wood, Cameron D. Wright, Gary Yang

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Esophageal cancer is a major health hazard in many parts of the world. Several advances have been made in staging procedures and therapeutic approaches. Unfortunately, esophageal cancer is often diagnosed late; therefore, most therapeutic approaches are palliative. Multidisciplinary team management is essential for treating patients with esophageat cancer. SCC and adenocarcinoma are the 2 major types of esophageat cancer. SCC is most common in endemic regions, whereas adenocarcinoma is most common in nonendemic regions. Smoking and alcohol abuse are major risk factors for SCC. Barrett's esophagus, obesity, and GERD seem to be major risk factors for development of adenocarcinoma of the esophagus or GE junction. Esophagectomy is considered the preferred primary treatment option for patients with resectable T1b, N0, or NX tumors. In medically fit patients with more advanced cancers, such as T1b, N1 to T4, N0-1, NX, or stage IVA, primary treatment options include definitive chemoradiation, preoperative chemotherapy, or chemoradiation followed by esophagectomy. Medically unfit patients may be offered definitive chemoradiation. Postoperative treatment is based on histology, surgical margins, and nodal status. In patients with SCC who have no residual disease at surgical margins (R0 resection), no further treatment is recommended, irrespective of their nodal status. Fluoropyrimidine-based chemoradiation is recommended for patients with node-positive and -negative adenocarcinoma who have T2, N0 tumors with high-risk features and T3, N0 tumors. Postoperative chemotherapy may be considered (only if they underwent preoperative chemotherapy) for patients with resectable adenocarcinoma of the lower esophagus and GE junction. All patients with residual disease at surgical margins (R1 and R2 resections) may be treated with fluoropyrimidine-based chemoradiation. Concurrent chemoradiation with a fluoropyrimidine-based regimen is recommended for unresectable disease in patients medically unfit for surgery and able to tolerate chemotherapy. Best supportive care is an integral part of treatment, especially in patients with locally advanced disease. Assessing disease severity and related symptoms is essential to initiate appropriate palliative interventions that will prevent and relieve suffering and improve quality of life for patients and their caregivers. Metastatic disease in patients with good performance status can be treated with chemotherapy plus best supportive care, whereas best supportive care is recommended for those with poor performance status. Endoscopic palliation of esophageal cancer has improved substantially because of improving technology. The NCCN Clinical Practice Guidelines in Oncology: Esophageal Cancer (in this issue; to view the most recent version, visit www.nccn.org) emphasize that considerable advances have been made in the treatment of locoregional esophageal cancer. Novel therapeutic modalities, such as targeted therapies, vaccines, gene therapy, and antiangiogenic agents, are being studied in clinical trials for patients with esophageal cancer. The panel encourages patients with esophageal cancer to participate in well-designed clinical trials to enable further advances.

Original languageEnglish (US)
Pages (from-to)818-848
Number of pages31
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume6
Issue number9
StatePublished - Oct 1 2008

Fingerprint

Esophageal Neoplasms
Drug Therapy
Neoplasms
Adenocarcinoma
Esophagectomy
Therapeutics
Clinical Trials
Active Immunotherapy
Angiogenesis Inhibitors
Barrett Esophagus
Gastroesophageal Reflux
Practice Guidelines
Genetic Therapy
Caregivers
Alcoholism
Histology
Obesity
Smoking
Quality of Life

Keywords

  • Chemoradiation
  • Chemotherapy
  • Combined modality therapy
  • Esophageal carcinoma
  • NCCN clinical practice guidelines
  • Resection
  • Surgery

ASJC Scopus subject areas

  • Oncology

Cite this

Ajani, J. A., Barthel, J. S., Bekaii-Saab, T., Bentrem, D. J., D'Amico, T. A., Fuchs, C. S., ... Yang, G. (2008). Esophageal cancer. JNCCN Journal of the National Comprehensive Cancer Network, 6(9), 818-848.

Esophageal cancer. / Ajani, Jaffer A.; Barthel, James S.; Bekaii-Saab, Tanios; Bentrem, David J.; D'Amico, Thomas A.; Fuchs, Charles S.; Gerdes, Hans; Hayman, James A.; Hazard, Lisa; Ilsonn, David H.; Kleinberg, Lawrence R.; McAleer, Mary Frances; Meropol, Neal J.; Mulcahy, Mary F.; Orringer, Mark B.; Osarogiagbon, Raymund U.; Posey, James A.; Sasson, Aaron R.; Scott, Walter J.; Shibata, Stephen; Strong, Vivian E.M.; Swisher, Stephen G.; Washington, Mary Kay; Willett, Christopher; Wood, Douglas E.; Wright, Cameron D.; Yang, Gary.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 6, No. 9, 01.10.2008, p. 818-848.

Research output: Contribution to journalArticle

Ajani, JA, Barthel, JS, Bekaii-Saab, T, Bentrem, DJ, D'Amico, TA, Fuchs, CS, Gerdes, H, Hayman, JA, Hazard, L, Ilsonn, DH, Kleinberg, LR, McAleer, MF, Meropol, NJ, Mulcahy, MF, Orringer, MB, Osarogiagbon, RU, Posey, JA, Sasson, AR, Scott, WJ, Shibata, S, Strong, VEM, Swisher, SG, Washington, MK, Willett, C, Wood, DE, Wright, CD & Yang, G 2008, 'Esophageal cancer', JNCCN Journal of the National Comprehensive Cancer Network, vol. 6, no. 9, pp. 818-848.
Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Fuchs CS et al. Esophageal cancer. JNCCN Journal of the National Comprehensive Cancer Network. 2008 Oct 1;6(9):818-848.
Ajani, Jaffer A. ; Barthel, James S. ; Bekaii-Saab, Tanios ; Bentrem, David J. ; D'Amico, Thomas A. ; Fuchs, Charles S. ; Gerdes, Hans ; Hayman, James A. ; Hazard, Lisa ; Ilsonn, David H. ; Kleinberg, Lawrence R. ; McAleer, Mary Frances ; Meropol, Neal J. ; Mulcahy, Mary F. ; Orringer, Mark B. ; Osarogiagbon, Raymund U. ; Posey, James A. ; Sasson, Aaron R. ; Scott, Walter J. ; Shibata, Stephen ; Strong, Vivian E.M. ; Swisher, Stephen G. ; Washington, Mary Kay ; Willett, Christopher ; Wood, Douglas E. ; Wright, Cameron D. ; Yang, Gary. / Esophageal cancer. In: JNCCN Journal of the National Comprehensive Cancer Network. 2008 ; Vol. 6, No. 9. pp. 818-848.
@article{3a9f449fbb7a4a89be1d7b6ce6d05cee,
title = "Esophageal cancer",
abstract = "Esophageal cancer is a major health hazard in many parts of the world. Several advances have been made in staging procedures and therapeutic approaches. Unfortunately, esophageal cancer is often diagnosed late; therefore, most therapeutic approaches are palliative. Multidisciplinary team management is essential for treating patients with esophageat cancer. SCC and adenocarcinoma are the 2 major types of esophageat cancer. SCC is most common in endemic regions, whereas adenocarcinoma is most common in nonendemic regions. Smoking and alcohol abuse are major risk factors for SCC. Barrett's esophagus, obesity, and GERD seem to be major risk factors for development of adenocarcinoma of the esophagus or GE junction. Esophagectomy is considered the preferred primary treatment option for patients with resectable T1b, N0, or NX tumors. In medically fit patients with more advanced cancers, such as T1b, N1 to T4, N0-1, NX, or stage IVA, primary treatment options include definitive chemoradiation, preoperative chemotherapy, or chemoradiation followed by esophagectomy. Medically unfit patients may be offered definitive chemoradiation. Postoperative treatment is based on histology, surgical margins, and nodal status. In patients with SCC who have no residual disease at surgical margins (R0 resection), no further treatment is recommended, irrespective of their nodal status. Fluoropyrimidine-based chemoradiation is recommended for patients with node-positive and -negative adenocarcinoma who have T2, N0 tumors with high-risk features and T3, N0 tumors. Postoperative chemotherapy may be considered (only if they underwent preoperative chemotherapy) for patients with resectable adenocarcinoma of the lower esophagus and GE junction. All patients with residual disease at surgical margins (R1 and R2 resections) may be treated with fluoropyrimidine-based chemoradiation. Concurrent chemoradiation with a fluoropyrimidine-based regimen is recommended for unresectable disease in patients medically unfit for surgery and able to tolerate chemotherapy. Best supportive care is an integral part of treatment, especially in patients with locally advanced disease. Assessing disease severity and related symptoms is essential to initiate appropriate palliative interventions that will prevent and relieve suffering and improve quality of life for patients and their caregivers. Metastatic disease in patients with good performance status can be treated with chemotherapy plus best supportive care, whereas best supportive care is recommended for those with poor performance status. Endoscopic palliation of esophageal cancer has improved substantially because of improving technology. The NCCN Clinical Practice Guidelines in Oncology: Esophageal Cancer (in this issue; to view the most recent version, visit www.nccn.org) emphasize that considerable advances have been made in the treatment of locoregional esophageal cancer. Novel therapeutic modalities, such as targeted therapies, vaccines, gene therapy, and antiangiogenic agents, are being studied in clinical trials for patients with esophageal cancer. The panel encourages patients with esophageal cancer to participate in well-designed clinical trials to enable further advances.",
keywords = "Chemoradiation, Chemotherapy, Combined modality therapy, Esophageal carcinoma, NCCN clinical practice guidelines, Resection, Surgery",
author = "Ajani, {Jaffer A.} and Barthel, {James S.} and Tanios Bekaii-Saab and Bentrem, {David J.} and D'Amico, {Thomas A.} and Fuchs, {Charles S.} and Hans Gerdes and Hayman, {James A.} and Lisa Hazard and Ilsonn, {David H.} and Kleinberg, {Lawrence R.} and McAleer, {Mary Frances} and Meropol, {Neal J.} and Mulcahy, {Mary F.} and Orringer, {Mark B.} and Osarogiagbon, {Raymund U.} and Posey, {James A.} and Sasson, {Aaron R.} and Scott, {Walter J.} and Stephen Shibata and Strong, {Vivian E.M.} and Swisher, {Stephen G.} and Washington, {Mary Kay} and Christopher Willett and Wood, {Douglas E.} and Wright, {Cameron D.} and Gary Yang",
year = "2008",
month = "10",
day = "1",
language = "English (US)",
volume = "6",
pages = "818--848",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "9",

}

TY - JOUR

T1 - Esophageal cancer

AU - Ajani, Jaffer A.

AU - Barthel, James S.

AU - Bekaii-Saab, Tanios

AU - Bentrem, David J.

AU - D'Amico, Thomas A.

AU - Fuchs, Charles S.

AU - Gerdes, Hans

AU - Hayman, James A.

AU - Hazard, Lisa

AU - Ilsonn, David H.

AU - Kleinberg, Lawrence R.

AU - McAleer, Mary Frances

AU - Meropol, Neal J.

AU - Mulcahy, Mary F.

AU - Orringer, Mark B.

AU - Osarogiagbon, Raymund U.

AU - Posey, James A.

AU - Sasson, Aaron R.

AU - Scott, Walter J.

AU - Shibata, Stephen

AU - Strong, Vivian E.M.

AU - Swisher, Stephen G.

AU - Washington, Mary Kay

AU - Willett, Christopher

AU - Wood, Douglas E.

AU - Wright, Cameron D.

AU - Yang, Gary

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Esophageal cancer is a major health hazard in many parts of the world. Several advances have been made in staging procedures and therapeutic approaches. Unfortunately, esophageal cancer is often diagnosed late; therefore, most therapeutic approaches are palliative. Multidisciplinary team management is essential for treating patients with esophageat cancer. SCC and adenocarcinoma are the 2 major types of esophageat cancer. SCC is most common in endemic regions, whereas adenocarcinoma is most common in nonendemic regions. Smoking and alcohol abuse are major risk factors for SCC. Barrett's esophagus, obesity, and GERD seem to be major risk factors for development of adenocarcinoma of the esophagus or GE junction. Esophagectomy is considered the preferred primary treatment option for patients with resectable T1b, N0, or NX tumors. In medically fit patients with more advanced cancers, such as T1b, N1 to T4, N0-1, NX, or stage IVA, primary treatment options include definitive chemoradiation, preoperative chemotherapy, or chemoradiation followed by esophagectomy. Medically unfit patients may be offered definitive chemoradiation. Postoperative treatment is based on histology, surgical margins, and nodal status. In patients with SCC who have no residual disease at surgical margins (R0 resection), no further treatment is recommended, irrespective of their nodal status. Fluoropyrimidine-based chemoradiation is recommended for patients with node-positive and -negative adenocarcinoma who have T2, N0 tumors with high-risk features and T3, N0 tumors. Postoperative chemotherapy may be considered (only if they underwent preoperative chemotherapy) for patients with resectable adenocarcinoma of the lower esophagus and GE junction. All patients with residual disease at surgical margins (R1 and R2 resections) may be treated with fluoropyrimidine-based chemoradiation. Concurrent chemoradiation with a fluoropyrimidine-based regimen is recommended for unresectable disease in patients medically unfit for surgery and able to tolerate chemotherapy. Best supportive care is an integral part of treatment, especially in patients with locally advanced disease. Assessing disease severity and related symptoms is essential to initiate appropriate palliative interventions that will prevent and relieve suffering and improve quality of life for patients and their caregivers. Metastatic disease in patients with good performance status can be treated with chemotherapy plus best supportive care, whereas best supportive care is recommended for those with poor performance status. Endoscopic palliation of esophageal cancer has improved substantially because of improving technology. The NCCN Clinical Practice Guidelines in Oncology: Esophageal Cancer (in this issue; to view the most recent version, visit www.nccn.org) emphasize that considerable advances have been made in the treatment of locoregional esophageal cancer. Novel therapeutic modalities, such as targeted therapies, vaccines, gene therapy, and antiangiogenic agents, are being studied in clinical trials for patients with esophageal cancer. The panel encourages patients with esophageal cancer to participate in well-designed clinical trials to enable further advances.

AB - Esophageal cancer is a major health hazard in many parts of the world. Several advances have been made in staging procedures and therapeutic approaches. Unfortunately, esophageal cancer is often diagnosed late; therefore, most therapeutic approaches are palliative. Multidisciplinary team management is essential for treating patients with esophageat cancer. SCC and adenocarcinoma are the 2 major types of esophageat cancer. SCC is most common in endemic regions, whereas adenocarcinoma is most common in nonendemic regions. Smoking and alcohol abuse are major risk factors for SCC. Barrett's esophagus, obesity, and GERD seem to be major risk factors for development of adenocarcinoma of the esophagus or GE junction. Esophagectomy is considered the preferred primary treatment option for patients with resectable T1b, N0, or NX tumors. In medically fit patients with more advanced cancers, such as T1b, N1 to T4, N0-1, NX, or stage IVA, primary treatment options include definitive chemoradiation, preoperative chemotherapy, or chemoradiation followed by esophagectomy. Medically unfit patients may be offered definitive chemoradiation. Postoperative treatment is based on histology, surgical margins, and nodal status. In patients with SCC who have no residual disease at surgical margins (R0 resection), no further treatment is recommended, irrespective of their nodal status. Fluoropyrimidine-based chemoradiation is recommended for patients with node-positive and -negative adenocarcinoma who have T2, N0 tumors with high-risk features and T3, N0 tumors. Postoperative chemotherapy may be considered (only if they underwent preoperative chemotherapy) for patients with resectable adenocarcinoma of the lower esophagus and GE junction. All patients with residual disease at surgical margins (R1 and R2 resections) may be treated with fluoropyrimidine-based chemoradiation. Concurrent chemoradiation with a fluoropyrimidine-based regimen is recommended for unresectable disease in patients medically unfit for surgery and able to tolerate chemotherapy. Best supportive care is an integral part of treatment, especially in patients with locally advanced disease. Assessing disease severity and related symptoms is essential to initiate appropriate palliative interventions that will prevent and relieve suffering and improve quality of life for patients and their caregivers. Metastatic disease in patients with good performance status can be treated with chemotherapy plus best supportive care, whereas best supportive care is recommended for those with poor performance status. Endoscopic palliation of esophageal cancer has improved substantially because of improving technology. The NCCN Clinical Practice Guidelines in Oncology: Esophageal Cancer (in this issue; to view the most recent version, visit www.nccn.org) emphasize that considerable advances have been made in the treatment of locoregional esophageal cancer. Novel therapeutic modalities, such as targeted therapies, vaccines, gene therapy, and antiangiogenic agents, are being studied in clinical trials for patients with esophageal cancer. The panel encourages patients with esophageal cancer to participate in well-designed clinical trials to enable further advances.

KW - Chemoradiation

KW - Chemotherapy

KW - Combined modality therapy

KW - Esophageal carcinoma

KW - NCCN clinical practice guidelines

KW - Resection

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=56049093472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56049093472&partnerID=8YFLogxK

M3 - Article

C2 - 18926093

AN - SCOPUS:56049093472

VL - 6

SP - 818

EP - 848

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 9

ER -